Abstract
Beat detection is a key step in the analysis of photo-plethysmogram (PPG) signals. The ‘MSPTD’ algorithm was recently identified as one of the most accurate beat detection algorithms, but its current open-source implementation is substantially more computationally expensive than other leading algorithms such as ‘qppgfast’. The aim of this work was to develop a more efficient, open-source implementation of the ‘MSPTD’ algorithm. Five potential improvements were identified to increase efficiency. Each potential improvement was evaluated in turn, and an optimal algorithm configuration named ‘MSPTDfast’ was developed which incorporated all of the improvements found to reduce algorithm execution time whilst not substantially reducing the accuracy of beat detection. Performance was assessed using data collected from young adults during a lunchbreak in the PPG-DaLiA dataset. The data consisted of wrist PPG signals acquired using an Empatica E4 device, alongside simultaneous ECG signals from which reference heartbeat timings were obtained. ‘MSPTDfast’ was found to be substantially more efficient than ‘MSPTD’ (a reduction in execution time of 72.3%), with minimal difference in beat detection accuracy (F1-score 87.8% vs. 87.7%). In addition, the performance of ‘MSPTDfast’ was much closer to that of the state-of-the-art ‘qppgfast’ algorithm than the ‘MSPTD’ algorithm, with a comparable F1-score (87.4% vs. 87.7%), and an execution time which was only 19.2% longer than that of ‘qppgfast’ (vs. 330.8% longer for ‘MSPTD’). In conclusion, ‘MSPTD-fast’ is an efficient and accurate open-source PPG beat detection algorithm with a substantially faster execution time than ‘MSPTD’. It is available under the permissive MIT licence.
Competing Interest Statement
P.H.C. has performed consultancy work for Cambridge University Technical Services, has received travel funds from VascAgeNet, and has received honoraria from IOP Publishing and Emory University (the latter not received personally). J.M. has performed consultancy work for BMS/ Pfizer and Omron.
Funding Statement
This study is funded by the British Heart Foundation [FS/20/20/34626].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://doi.org/10.24432/C53890
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Re-ran analysis after realising that the code for MSPTDfast (v.1) was using both peaks and onsets detection due to a typo in the code. To do this, I: - corrected the code (and made a couple of minor refinements) - re-ran the analysis on a different computer - updated the manuscript to state that MSPTDfast (v.1.1) identified both peaks and onsets. - updated the manuscript with the updated results
Data Availability
This study used openly available data that were originally located at: https://doi.org/10.24432/C53890
